

Scott T Tagawa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8511197/scott-t-tagawa-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

8,542
citations

42
h-index

91
g-index

215
ext. papers

11,308
ext. citations

5.5
avg, IF

5.57
L-index

#	Paper	IF	Citations
193	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
192	Use of Biosimilar Medications in Oncology.. <i>JCO Oncology Practice</i> , 2022 , OP2100771	2.3	1
191	Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis.. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022 , 31, 106297	2.8	
190	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 532-532	2.2	
189	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 77-77	2.2	1
188	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 139-139	2.2	
187	Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 96-96	2.2	0
186	TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS581-TPS581	2.2	0
185	BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotypePhase 2a interim results.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 121-121	2.2	
184	Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 37-37	2.2	
183	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS216-TPS216	2.2	1
182	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 434-434	2.2	1
181	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. <i>Nature Communications</i> , 2022 , 13, 1878	17.4	1
180	What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes.. <i>European Urology Open Science</i> , 2022 , 40, 58-94	0.9	0
179	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.. <i>European Urology Open Science</i> , 2021 , 34, 70-78	0.9	0
178	Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. <i>Cancer Medicine</i> , 2021 , 10, 8570-8580	4.8	3
177	Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. <i>European Urology Focus</i> , 2021 , 7, 254-257	5.1	4

176	Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5042-5042	2.2	1
175	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5095-TPS5095	2.2	
174	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5087-TPS5087	2.2	0
173	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5091-TPS5091	2.2	0
172	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5055-5055	2.2	
171	Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5015-5015	2.2	4
170	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , 2021 , 4, 785	6.7	0
169	Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. <i>Annals of Neurology</i> , 2021 , 90, 159-169	9.4	8
168	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , 2021 , 12, 3372	17.4	3
167	Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted emitting radionuclide therapies in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021 , 81, 279-285	4.2	4
166	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2642-2651	8.8	14
165	Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. <i>Journal of Urology</i> , 2021 , 205, 554-560	2.5	1
164	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS188-TPS188	2.2	0
163	Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 1032-1040	6.2	5
162	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 140-140	2.2	
161	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 41-41	2.2	4
160	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 630589	5.3	8
159	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 120-120	2.2	1

158	Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 46-46	2.2	1
157	Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 22-22	2.2	
156	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 158-158	2.2	
155	Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 59	6.3	1
154	Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021 , 32, 1243-1244	2.4	
153	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2474-2485	2.2	57
152	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021 , 5, 74	9.8	4
151	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021 , 39, 2486-2496	2.2	10
150	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , 2021 , 26, e1971-e1981	5.7	1
149	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
148	Reply to T. Powles et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3412-3413	2.2	
147	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 569-576	2.8	1
146	Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. <i>JAMA Oncology</i> , 2021 , 7, 1642-1643	13.4	1
145	Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021 , 385, 1091-1103	59.2	202
144	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 528-547	2.8	
143	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 447-456	3.3	0
142	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	18
141	CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. <i>Molecular Therapy</i> , 2020 , 28, 1238-1250	11.7	7

140	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1157-1164	6.1	23
139	An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 863-870	4	2
138	Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2020 , 25, 477-e895	5.7	21
137	Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1736-1743	2.2	21
136	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1653-1668	15.9	56
135	Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3055-3055	2.2	1
134	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3552-3552	2.2	3
133	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5015-5015	2.2	10
132	Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5027-5027	2.2	8
131	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5543-5543	2.2	7
130	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5560-5560	2.2	7
129	Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5092-TPS5092	2.2	2
128	Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5590-TPS5590	2.2	1
127	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 114-114	2.2	13
126	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 15-15	2.2	12
125	Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 511-511	2.2	6
124	Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 40-40	2.2	
123	Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 45-45	2.2	0

122	Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17503-e17503	2.2	2
121	Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 12090-12090	2.2	
120	Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5096-TPS5096	2.2	
119	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5594-TPS5594	2.2	2
118	NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2020 , 38, 1383-1389	4.3	4
117	PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. <i>Prostate</i> , 2020 , 80, 99-108	4.2	21
116	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 105-120	21.7	35
115	Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 848.e9-848.e16	2.8	18
114	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020 , 11, 6195	17.4	6
113	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020 , 80, 1273-1296	4.2	11
112	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020 , 4, 370-381	3.6	66
111	Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. <i>Stroke</i> , 2019 , 50, 3259-3264	6.4	6
110	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , 2019 , 121, 7-18	7.5	79
109	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15
108	Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 2561-2569	6.4	58
107	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	56
106	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1120-1129	2.2	171
105	Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. <i>Journal of Oncology Practice</i> , 2019 , 15, 343-345	3.1	1

104	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 381, 338-348	59.2	456
103	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019 , 10, 2977	17.4	71
102	Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5013-5013	2.2	1
101	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 272-272	2.2	5
100	Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 354-354	2.2	49
99	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS495-TPS495	2.2	3
98	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS348-TPS348	2.2	3
97	Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. <i>Physical Biology</i> , 2019 , 16, 036003	3	10
96	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019 , 25, 43-51	12.9	110
95	Arterial thromboembolic events preceding the diagnosis of cancer in older persons. <i>Blood</i> , 2019 , 133, 781-789	2.2	74
94	Expression of AR-V7 and ARv in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. <i>Clinical Cancer Research</i> , 2019 , 25, 1880-1888	12.9	61
93	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018 , 73, 687-693	10.2	70
92	A critical review on ramucirumab in the treatment of advanced urothelial cancer. <i>Future Oncology</i> , 2018 , 14, 1049-1061	3.6	4
91	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018 , 78, 775-789	4.2	25
90	Antibody-Drug Conjugates in Bladder Cancer. <i>Bladder Cancer</i> , 2018 , 4, 247-259	1	20
89	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , 2018 , 9, 2404	17.4	149
88	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4503-4503	2.2	42
87	Upper tract urothelial carcinoma is non-basal and T-cell depleted.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4525-4525	2.2	1

86	Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 450-450	2.2	9
85	Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS399-TPS399	2.2	14
84	Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 172-172	2.2	
83	Nadir testosterone (T) following in-situ polymer delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 204-204	2.2	
82	Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17039-e17039	2.2	78
81	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3251-3258	2.2	78
80	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2017 , 57, 16-27	14.4	107
79	Uncommon Cancers of the Prostate 2017 , 68-96		
78	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	23
77	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3181-3188	2.2	53
76	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2266-2277	40	121
75	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 135-149	5.4	4
74	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016 , 48, 1490-1499	36.3	161
73	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1510-9	12.9	96
72	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016 , 22, 298-305	50.5	775
71	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1500-9	2.2	65
70	Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e75-9	3.3	54
69	Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2559-2559	2.2	2

68	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5007-5007	2.2	3
67	Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5022-5022	2.2	5
66	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 354-354	2.2	3
65	Archexin, a novel AKT-1 specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 550-550	2.2	3
64	Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 379-379	2.2	
63	Fractionated dose radiolabeled anti prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 205-205	2.2	
62	Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 268-268	2.2	
61	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5277-85	12.9	129
60	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
59	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , 2015 , 1, 466-74	13.4	207
58	Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4513-4513	2.2	1
57	Defining a molecular subclass of treatment resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5004-5004	2.2	3
56	A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 144-144	2.2	12
55	Fractionated dose radiolabeled anti prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 194-194	2.2	1
54	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 197-197	2.2	2
53	Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 295-295 ^{2.2}	2.2	7
52	Outcomes of preoperative chemotherapy in bladder cancer patients including node-positive disease.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 370-370	2.2	
51	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 158-158	2.2	1

50	Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 290-290	2.2	
49	Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate-specific membrane antigen (PSMA) antibody J591.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 164-164	2.2	
48	Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 199-199	2.2	
47	Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate-specific membrane antigen (PSMA) antibody J591.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5054-5054	2.2	
46	Use and outcomes of metastasectomy in older patients with urothelial cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15506-e15506	2.2	
45	Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5031-5031	2.2	
44	Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3360-4	2.2	22
43	Immunologics and chemotherapeutics for renal cell carcinoma. <i>Seminars in Interventional Radiology</i> , 2014 , 31, 91-7	1.6	9
42	ERG induces taxane resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2014 , 5, 5548	17.4	81
41	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 692-701	6.4	78
40	Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5025-5025	2.2	1
39	Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5064-5064	2.2	7
38	Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 204-204	2.2	4
37	Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 205-205	2.2	1
36	Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 25-25	2.2	3
35	Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 177-177	2.2	2
34	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013 , 111, 44-52	5.6	55
33	Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. <i>Neoplasia</i> , 2013 , 15, 1-10	6.4	165

32	PSMA-targeted dendrimers: a patent evaluation (WO2012078534). <i>Expert Opinion on Therapeutic Patents</i> , 2013 , 23, 665-8	6.8	3
31	Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 5182-91	12.9	299
30	Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. <i>Frontiers in Oncology</i> , 2013 , 3, 214	5.3	27
29	Noninvasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: A prognostic tool for metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11081-11081	2.2	3
28	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS5096-TPS5096 ^{2.2}	2.2	4
27	TAXYENERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS5100-TPS5100	2.2	3
26	Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 121-121	2.2	1
25	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 31-31	2.2	5
24	Association of CTCAE v4 grading of hypertension with toxicity in patients with renal cancer receiving vascular endothelial growth factor (VEGF)-targeting agents.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 447-447	2.2	3
23	Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. <i>PLoS ONE</i> , 2013 , 8, e85143	3.7	34
22	Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15600-e15600	2.2	1
21	Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. <i>PLoS ONE</i> , 2012 , 7, e35976	3.7	161
20	Prostate-specific membrane antigen-based therapeutics. <i>Advances in Urology</i> , 2012 , 2012, 973820	1.6	59
19	Challenges in recognizing treatment-related neuroendocrine prostate cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, e386-9	2.2	146
18	The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer. <i>Prostate Cancer</i> , 2012 , 2012, 280278	1.9	5
17	D-Dimer Levels Among Cancer Patients with Unsuspected Pulmonary Embolism: Clinical Correlates and Relevance. <i>Blood</i> , 2012 , 120, 1154-1154	2.2	2
16	Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 100-100	2.2	3
15	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 173-173	2.2	3

14	Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 190-190	2.2	
13	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 120-120	2.2	
12	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 110-110	2.2	
11	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4649-4649	2.2	
10	Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. <i>Cancer Research</i> , 2011 , 71, 6019-29	10.1	341
9	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , 2011 , 1, 487-95	24.4	550
8	PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2011 , 41, 29-44	5.4	70
7	A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 443-8	2.7	9
6	Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2011 , 13, 785-6	2.8	1
5	Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. <i>Advances in Urology</i> , 2010 , 179250	1.6	8
4	Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. <i>Cancer</i> , 2010 , 116, 1075-83	6.4	109
3	Tinzaparin Is Effective and Safe for the Treatment and Extended Secondary Prophylaxis In Cancer Patients with Venous Thromboembolism.. <i>Blood</i> , 2010 , 116, 1104-1104	2.2	1
2	Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. <i>BJU International</i> , 2008 , 102, 1086-91	5.6	10
1	A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals		